Eeson Rajendra

9PUBLICATIONS
100CO-AUTHORS
Molecular targetsCheminformatics and quantitative structure-activity relationshipsCell development, proliferation and deathRadiation therapyCharacterisation of biological macromolecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Jul 13, 2026
The Pharmacologic Profile of ART6043, a First-in-Class Clinical DNA Polymerase Theta Polymerase Domain Inhibitor Potentiating PARP Inhibitor Efficacy.

|Jun 12, 2026
SHLD2 loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapy.

|Dec 08, 2025
Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapy.

Eeson Rajendra, Claudio A Lademann, Bethany Mason

|Dec 08, 2025
Discovery of ART5537: A Potent and Selective Small-Molecule Probe for EXO1.

Sam E Mann, Owen A Davis, Jörg Bomke

|Sep 17, 2025
Fragment-Based Discovery and Structure-Led Optimization of MSC778, the First Potent, Selective, and Orally Bioavailable FEN1 Inhibitor.

Sam E Mann, Julien Lefranc, Omar Alkhatib

|Feb 28, 2024
Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types.

Patrick G Pilié, Virginia Giuliani, Wei-Lien Wang

Pageof 2

Frequent Collaborators

5 joint publications

Helen M R Robinson

5 joint publications

Robert A Heald

5 joint publications

Graeme C M Smith

4 joint publications

Diego Grande